In a clinical trial involving 340 patients across seven institutions, SANSA obtained its initial FDA clearance in 2024, demonstrating its accuracy in comparison to the gold-standard polysomnography. This innovative test incorporates nine distinct physiological channels, such as oximetry, respiratory effort, sleep/wake staging, and a reference electrocardiogram (ECG), into a single patch worn on the chest. This integration allows for a comprehensive understanding of cardiopulmonary health and provides valuable insights.